SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid a broader crypto market downturn, with community discussions focused on identifying potential bottom prices and debating the asset's long-term viability. Some traders are expressing frustration with the recent price action and broader market conditions, while others are highlighting Solana's resilience compared to other cryptocurrencies and accumulating positions. The community is also buzzing about meme coins in the Solana ecosystem.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending amid discussions about its potential in the DePIN sector and anticipation for its Layer 1 release, though some express frustration with the project's slow progress and marketing. Community members debate whether XYO can deliver on its promises and achieve mainstream adoption, with some pointing to its established network while others cite concerns about its performance and management. Speculation about potential partnerships and the impact of the broader crypto market on XYO's price are also circulating.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN) is trending amid discussions about potential pump-and-dump schemes and its volatile price action. Community members are debating its long-term potential, especially in anticipation of the Goliath mainnet launch, while also pointing out concerns about manipulation and comparing its performance to other cryptocurrencies like $SWFTC and $XRP. Some traders express frustration with the coin's inability to sustain gains, while others remain bullish, citing upcoming developments and potential for high transaction speeds.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoa is trending due to positive options activity and community bullish sentiment, fueled by discussions of aluminum's strong fundamentals and potential for upward price movement. Traders are actively discussing call options with various strike prices and expiration dates, reflecting optimism about Alcoa's near-term and long-term prospects. Some analysts point to undervaluation and improving charts within the aluminum sector as additional catalysts.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

IDYA is trending due to positive data from a Phase 2 trial of their cancer drug, Darovasertib, leading to potential regulatory approval. The community is also discussing the company's robust pipeline, recent analyst upgrades, and a potential future buyout. A recent stock offering is also being discussed.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as investors discuss potential M&A activity and speculate on the reasons behind the stock's recent price movements, including theories about institutional accumulation and short squeezes. The community is also focused on the upcoming earnings report and the potential for positive news regarding pipeline developments, including SG-001, and label expansion which could impact the company's growth trajectory amid broader sector rotation into biotech. Options activity is high with community members weighing in on their call positions and long-term outlook.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as the community debates its future, with some expressing frustration over its price performance while others remain optimistic about its underlying technology and staking rewards. Discussions revolve around potential catalysts like a token cap and the possible impact of Polkadot 2.0, alongside speculation about Web3 integration and the TikTok deal.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital (MARA) is trending as Bitcoin's price fluctuations trigger volatility in mining stocks, with community debates centering on its potential oversold status and possible short squeeze opportunities. Some investors are concerned about the company's management and profitability amid broader market downturns, while others highlight its potential AI pivot and significant Bitcoin holdings. Technical analysis and options flow are being closely watched for signals of a trend reversal.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to discussions around its expansion into Africa and its Q3 earnings report, as well as analysts raising price targets. The community is also closely watching Walmart's partnership with GIGA, a supplements company, and the potential impact on Q4 guidance. Additionally, Walmart's move to the Nasdaq and potential impact to low-income consumers is being discussed.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo (MLGO) is trending as traders discuss its potential for a short squeeze and compare it to other Chinese stocks known for volatile runs. The community is analyzing technical indicators, anticipating a breakout, and speculating on news or events that could act as a catalyst. Some investors are expressing concern about dilution and its long-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $20.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. dropped their price objective on shares of Agios Pharmaceuticals from $37.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday...

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen

Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading Volume After Analyst Upgrade

Agios Pharmaceuticals (NASDAQ:AGIO) Sees Unusually-High Trading Volume After Analyst Upgrade...

HC Wainwright Lowers Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $48.00

HC Wainwright lowered their price objective on Agios Pharmaceuticals from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Thursday...

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to "Sector Perform" at Royal Bank Of Canada

Royal Bank Of Canada cut Agios Pharmaceuticals from an "outperform" rating to a "sector perform" rating and set a $28.00 target price on the stock. in a report on Wednesday...

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.

Stock Traders Purchase High Volume of Agios Pharmaceuticals Call Options (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 8,407 call options on the stock. This is...

Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 12-Month Low - Here's Why

Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 1-Year Low - Here's What Happened...

<ul class="summary-bullets"><li>Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the mixed Phase 3 readout.</li><li>BofA, RBC, and H.C. Wainwright cut price targets, flagging a more uncertain path toward potential FDA approval.</li><li>Stocktwits traders debated the drop, with some buying the dip ahead of the upcoming FDA submission timeline.</li></ul>Agios Pharmaceuticals, Inc. shares crashed to their worst session on record on Wednesday after the company reported mixed late-stage trial results for its sickle cell disease treatment, triggering a wave of sharply lower analyst price targets.The stock closed down 51% at $22.34 before edging up 0.9% in after-hours trading.<h2 class="st-heading-2">Wall Street Turns Cautious</h2>Bank of America Securities (BofA) lowered the firm’s price target to $32 from $54 and maintained a 'Buy' rating. The note said the RISE UP study showed mitapivat met the primary hemoglobin endpoint but delivered “only modest directional benefit” for sickle cell pain crises and fatigue. While the company has previously said that hitting either primary endpoint would be sufficient for approval, BofA wrote that the results now point to “an uncertain regulatory and commercial path forward.”RBC Capital took a more cautious stance, downgrading Agios to 'Sector Perform' from 'Outperform' and slashing its target to $28 from $57. The firm wrote that although mitapivat is “clearly active,” it “fell short on the most important endpoints for patients,” noting gaps in crisis reduction, hospitalization, and fatigue. RBC said the changes reflect lower odds of success for the sickle cell program and reduced potential uptake even if the drug is ultimately approved.H.C. Wainwright also lowered its target to $48 from $56, while reiterating a 'Buy' rating. The firm called the market reaction “overdone” and said it remains “cautiously optimistic” about eventual FDA approval, citing the Oxbryta precedent and the absence of new safety issues, though it acknowledged that the data “increase some uncertainty.”<h2 class="st-heading-2">Trial Results&nbsp;</h2>The Wave of analyst downgrades came after Agios released topline data from its Phase 3 RISE UP study in sickle cell disease, the larger of its two key readouts before year-end 2025. The company reported that mitapivat met the primary endpoint of hemoglobin response, achieving a statistically significant improvement compared with placebo. It also showed positive effects on hemoglobin concentration and indirect bilirubin levels.However, Agios said the study did not show a statistically significant reduction in sickle cell pain crises and reported no improvement in fatigue, an important quality-of-life measure for patients. Agios plans to share the full clinical program with the FDA in the first quarter of 2026 as it prepares to pursue potential U.S. approval.<h2 class="st-heading-2">Competitors Gain On Agios Miss</h2>Leerink said that early Phase 1b data for Fulcrum Therapeutics’ pociredir suggest a “potentially differentiated and favorable efficacy profile” compared with mitapivat, noting the limits of direct comparison. Oppenheimer said the Agios outcome may be viewed as removing competitive pressure for Fulcrum, adding that the RISE UP results resembled HOPE, with marginal improvements in hemoglobin and no statistical significance for vaso-occlusive crises. The firm reiterated an 'Outperform' rating on Fulcrum.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Date</h2>On Stocktwits, retail sentiment for Agios was ‘extremely bullish’ amid a 6,400% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:971/140;" src="https://news.stocktwits-cdn.com/agio_ss_png_9b70c6d993.webp" alt="agio ss.png" width="971" height="140"><figcaption>AGIO sentiment and message volume as of November 21 | Source: Stocktwits</figcaption></figure>One user said, “I'll load more tomorrow and Friday. Need to be ready for December 6th FDA approval. Should skyrocket!!!”<stembedurl>https://stocktwits.com/murphylaw/message/636840528</stembedurl>Another user argued the selloff was excessive, saying the strong hemoglobin response and clean safety profile still supported a viable approval path, adding that one missed endpoint was unlikely to derail progress and that "it doesn’t take a perfect score for approval."<stembedurl>https://stocktwits.com/Mr_patience_MAN/message/636821985</stembedurl><a href="https://stocktwits.com/symbol/AGIO">Agios’ stock</a> has declined 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Agios Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug

Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the mixed Phase 3 readout.

Equity

Noteworthy Wednesday Option Activity: AGIO, VLO, AMTM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Agios Pharmaceuticals Inc (Symbol: AGIO), where a total of 24,712 contracts have traded so...

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGIO News

AGIOAgios Pharmaceuticals Inc